

April 30, 2026

To,  
The Listing Department,  
**BSE LIMITED,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai- 400 001

To,  
The Listing Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C-1,  
G-Block, Bandra Kurla Complex,  
Mumbai -400051

**Scrip Code: 543349**

**NSE Symbol: ACUTAAS**

**Subject: Investor Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on fourth quarter & year ended financial results as on March 31, 2026 and other business matters.

This Investor Presentation will also be available on the website of the Company  
[www.acutaas.com](http://www.acutaas.com).


Kindly take the same on record.

Yours faithfully,  
**For, ACUTAAS CHEMICALS LIMITED**



**Ekta Kumari Srivastava**  
**Company Secretary & Compliance Officer**

Encl: Presentation



# EARNINGS PRESENTATION

**APRIL 2026**



## Mr. Naresh Patel

Executive Chairman and Managing Director

"I am pleased to report a strong close to FY26, with Q4 revenue from operations reaching Rs. 4,328 million – up 40.3% year-on-year – and our highest ever PAT margin of 31.0%.

Our strategy is clear: build a diversified chemicals business across three high-growth verticals – Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. By scaling these in parallel, we are de-risking our revenue base while creating multiple independent engines of compounding, long-term growth.

We enter FY27 from a position of strength. I am confident of delivering 25% revenue growth in FY27."

(Mn.)

Revenue for Q4 FY26

₹4,328

YoY ▲  
40.3%

EBITDA for Q4 FY26

₹1,835

YoY ▲  
116.0%

PAT for Q4 FY26


₹1,343

YoY ▲  
114.1%

# Q4 FY26 Financial Performance – Key Metrics


## Revenue from Operations

(₹ Mn.)




## EBITDA & EBITDA Margin

(₹ Mn.)



## PAT

(₹ Mn.)



## Q4 FY26 Earnings & Business Highlights

### Pharma Intermediates

CDMO continues strong growth momentum;  
Supported by steady Non-CDMO business

### Specialty Chemicals

Strong recovery in Semiconductor Business (BFC)  
driven by steady commodity chemicals business

### Cost efficiencies

and product mix drove  
strong EBITDA expansion


### Highest-ever quarterly PAT

Driven by strong  
EBITDA margins and Other Income

# FY26 Financial Performance – Key Metrics


## Revenue from Operations

(₹ Mn.)




## EBITDA & EBITDA Margin

(₹ Mn.)



## PAT

(₹ Mn.)



## FY26 Earnings & Business Highlights

### Pharma Intermediates

Strong CDMO ramp-up lead to Solid growth supported by steady Non-CDMO Business

### Specialty Chemicals

Steady growth in Commodity chemicals offset by slight degrowth in Semiconductor Business (BFC)

### Cost efficiencies

and improved CDMO contribution led to margin expansion

### PAT more than doubled

Driven by strong EBITDA margins and Other Income


# Q4 & FY26 Financial Performance – P&L Statement

Particulars (Rs. Mn)	Q4FY26	Q4FY25	YoY-Q	Q3FY26	QoQ	FY26	FY25	YoY
<b>Revenue from Operations</b>	<b>4,328</b>	3,085	40.3%	<b>3,932</b>	10.1%	<b>13,394</b>	<b>10,069</b>	33.0%
COGS	1,644	1,625		1,692		5,660	5,522	
<b>Gross Profit</b>	<b>2,683</b>	<b>1,460</b>	83.8%	<b>2,240</b>	19.8%	<b>7,734</b>	<b>4,547</b>	70.1%
<i>Gross Margin</i>	62.0%	47.3%		57.0%		57.7%	45.2%	
Employee Benefits Expenses	333	233		299		1,176	837	
Other Expenses	515	377		435		1,754	1,390	
<b>Total Expenses</b>	<b>2,493</b>	<b>2,235</b>	11.6%	<b>2,425</b>	2.8%	<b>8,591</b>	<b>7,748</b>	10.9%
<b>EBITDA</b>	<b>1,835</b>	<b>850</b>	116.0%	<b>1,507</b>	21.8%	<b>4,804</b>	<b>2,321</b>	107.0%
<i>EBITDA Margin</i>	42.4%	27.5%		38.3%		35.9%	23.0%	
Depreciation and amortization	96	73		98		360	266	
<b>PBIT</b>	<b>1,739</b>	<b>777</b>	123.9%	<b>1408</b>	23.5%	<b>4,444</b>	<b>2,055</b>	116.3%
Finance costs	12	6		9		33	62	
Other Income	111	58		47		416	169	
<b>PBT</b>	<b>1,838</b>	<b>828</b>	121.9%	<b>1447</b>	27.1%	<b>4,827</b>	<b>2,162</b>	123.3%
Tax Expense	495	201		384		1264	557	
<b>PAT</b>	<b>1,343</b>	<b>627</b>	114.1%	<b>1062</b>	26.4%	<b>3,564</b>	<b>1,604</b>	122.2%
<i>PAT Margin</i>	31.0%	20.3%		27.0%		26.6%	15.9%	

# Financial Performance over the years – Key Metrics


## Revenue from Operations- Growth Trends

(₹ Mn.)




## EBITDA and EBITDA Margins

(₹ Mn. & %)




## Revenue – by Business Verticals

(%)




## Returns Profile<sup>#</sup>

(%)



## PAT and PAT Margins

(₹ Mn & %)



Note: PAT for FY24 is adjusted for Exceptional Items

<sup>#</sup> ROE and ROCE adjusted for Cash & Cash Equivalents, Exceptional Items, CWIP

# Financial Performance over the years - Profit and Loss

Particulars (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	3,406	5,201	6,167	7,175	10,069	13,394
Other Income	14	28	43	75	169	416
<b>Total Income</b>	<b>3,420</b>	<b>5,229</b>	<b>6,210</b>	<b>7,250</b>	<b>10,238</b>	<b>13,810</b>
Cost of materials consumed	1,749	2,823	3,459	4,402	5,698	5,950
Changes in Inventories <sup>1</sup>	48	(95)	(150)	(285)	(176)	(290)
Employee benefits expenses	210	414	488	631	837	1,176
Finance cost	56	64	24	59	62	33
Depreciation and amortisation expenses	42	101	123	161	266	360
Other expenses	598	1,008	1,144	1,142	1,390	1,754
<b>Total Expense</b>	<b>2,703</b>	<b>4,315</b>	<b>5,088</b>	<b>6,110</b>	<b>8,077</b>	<b>8,982</b>
<b>Profit before tax and exceptional items</b>	<b>717</b>	<b>914</b>	<b>1,122</b>	<b>1,140</b>	<b>2,162</b>	<b>4,827</b>
Exceptional profit / (loss)	-	-	-	(321)	-	-
Tax expense	177	195	289	332	557	1,264
<b>Profit for the year</b>	<b>540</b>	<b>719</b>	<b>833</b>	<b>487</b>	<b>1,604</b>	<b>3,564</b>


# Financial Performance over the years - Balance Sheet

Assets (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	FY26
Property, plant and equipment	1,422	1,584	1,844	3,229	4,629	5,828
Right of use assets	184	194	374	372	424	505
Capital work-in-progress	2	30	255	1,254	1,303	3,324
Goodwill	-	-	203	568	568	1,043
Other intangible assets	257	267	211	103	83	72
Investments	14	17	17	2	2	2
Other financial assets	27	108	65	26	49	82
Current tax assets (net)	-	49	32	25	2	-
Other non-current assets	64	97	129	447	517	171
<b>Total non-current assets</b>	<b>1,970</b>	<b>2,346</b>	<b>3,130</b>	<b>6,026</b>	<b>7,577</b>	<b>11,027</b>
Inventories	604	1,122	1,192	1,567	1,799	2,313
Trade receivables	1,207	1,637	2,303	2,064	2,905	3,626
Cash and cash equivalents	27	103	305	297	1,852	2,156
Other bank balances	-	893	281	236	637	93
Loans	3	6	13	16	22	26
Other current assets	321	481	445	753	701	599
<b>Total current assets</b>	<b>2,162</b>	<b>4,291</b>	<b>4,571</b>	<b>4,958</b>	<b>7,916</b>	<b>8,813</b>
<b>Total assets</b>	<b>4,133</b>	<b>6,589</b>	<b>7,669</b>	<b>10,959</b>	<b>15,493</b>	<b>19,840</b>

Liabilities & Equity (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	FY26
<b>Shareholder's equity</b>	<b>1,669</b>	<b>5,223</b>	<b>5,939</b>	<b>6,828</b>	<b>13,201</b>	<b>17,108</b>
Financial Liabilities	726	6	6	1,136	48	91
Provisions	44	4	7	13	25	46
Deferred tax liabilities (net)	33	63	88	130	196	287
<b>Total non-current liabilities</b>	<b>803</b>	<b>73</b>	<b>101</b>	<b>1,280</b>	<b>269</b>	<b>424</b>
Borrowings	640	3	30	1,030	82	265
Trade payables	848	1,184	1,420	1,346	1,561	1,539
Other current liabilities	151	46	64	344	135	124
Provisions	10	60	114	132	245	325
Current tax liabilities (net)	11	-	-	-	-	55
<b>Total current liabilities</b>	<b>1,660</b>	<b>1,293</b>	<b>1,628</b>	<b>2,852</b>	<b>2,023</b>	<b>2,308</b>
<b>Total liabilities</b>	<b>2,463</b>	<b>1,366</b>	<b>1,730</b>	<b>4,131</b>	<b>2,292</b>	<b>2,732</b>
<b>Total equity and liabilities</b>	<b>4,133</b>	<b>6,589</b>	<b>7,669</b>	<b>10,959</b>	<b>15,493</b>	<b>19,840</b>

# Shareholder Information

Shareholding as on 31<sup>st</sup> March 2026



Source: BSE

Share Information as on 31<sup>st</sup> March 2026

NSE Ticker	<b>ACUTAAS</b>
BSE Ticker	<b>543349</b>
Market Cap (₹ Cr.)	<b>20,948</b>
Shares Outstanding	<b>8,18,71,122</b>
3M ADTV (Shares)	<b>4,27,895</b>
3M ADTV (₹ Cr.)	<b>88.4</b>
Industry	<b>Specialty Chemicals</b>

Source: NSE



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Acutaas Chemicals Ltd.

## Contact Us

For more information please contact:

---

### **Acutaas Chemicals Limited**

**Ekta Srivastava**

Company Secretary & Compliance Officer  
[cs@acutaas.com](mailto:cs@acutaas.com)

**Rahul Thakur**

Senior Manager – Investor Relations  
[Rahul.thakur@acutaas.com](mailto:Rahul.thakur@acutaas.com)